Session » Genetics, Genomics and Proteomics Poster I

Date: Sunday, November 5, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 183

Allele-Dependent Binding of a Viral Protein to Autoimmune Disease-Associated Genetic Variants

9:00AM-11:00AM: Abstract Number: 184

An Epigenome-Guided Approach to Causal Variant Discovery in Autoimmune Disease

9:00AM-11:00AM: Abstract Number: 173

Applying Urine Proteomics for Discovery of Lupus Nephritis Damage Biomarkers in a Pediatric Cohort

9:00AM-11:00AM: Abstract Number: 164

Association of Natural Killer Cell Ligand Polymorphism, HLA-C Asn80Lys, with the Development of Anti-SSA/Ro Associated Congenital Heart Block

9:00AM-11:00AM: Abstract Number: 167

Differentially Co-Expressed Gene Networks in Previously DMARD-Naïve Patients with Early RA Achieving Sustained Drug-Free Remission after Step-up Methotrexate Therapy

9:00AM-11:00AM: Abstract Number: 171

Finding Transcriptional Regulators Central to RA with Transcriptomics of IL17 Dose Response, Time Series, and siRNA Silencing in Stromal Cells

9:00AM-11:00AM: Abstract Number: 182

Genetic Determinants of Fatigue in Primary Sjögren`s Syndrome – a Genome Wide Association Study

9:00AM-11:00AM: Abstract Number: 170

Genome-Wide Association Study of Clinically-Ascertained Gout and Subtypes Identifies Multiple Susceptibility Loci Including Transporter Genes

9:00AM-11:00AM: Abstract Number: 178

Genome-Wide DNA Methylation Study in Lupus in an Admixed Mexican Population

9:00AM-11:00AM: Abstract Number: 180

Identification of a Functional Susceptible Variant in Distal Enhancer of Mir-146a By CRISPR-Cas9

9:00AM-11:00AM: Abstract Number: 181

Identification of Disease-Susceptible Lncrna Contributed to Abnormal Activation of Type I Interferon Pathway in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 168

Identification of Novel Susceptibility Loci in a Large UK Cohort of Juvenile Idiopathic Arthritis (JIA) Cases

9:00AM-11:00AM: Abstract Number: 166

Integrative Systems Biology Approach Identifies Key Transcription Factors and Novel Rheumatoid Arthritis (RA) and Individualized Therapeutic Targets

9:00AM-11:00AM: Abstract Number: 177

Intronic Variants of the B-Cell Proliferator RASGRP3 Affect Its Expression, and Might Contribute to Lupus Risk

9:00AM-11:00AM: Abstract Number: 179

Mass Spectrometry Imaging of Synovium: A Novel Approach to Classify the Rheumatoid and Psoriatic Arthritis Patients

9:00AM-11:00AM: Abstract Number: 169

New Autoinflammatory Phenotype Associated with Homozygous AGBL3 Variant

9:00AM-11:00AM: Abstract Number: 172

Optimizing Precision Medicine By Using Genetics to Assign Diagnostic Prior Probabilities to Patients with Synovitis

9:00AM-11:00AM: Abstract Number: 175

Precisely Controlled Differential Gene Expression System to Investigate the Effect of eQTL

9:00AM-11:00AM: Abstract Number: 165

Rheumatoid Arthritis Risk Polymorphisms in CCR6, SNP and Estrogen-Dependent Response to Immune Mediator Gene Expression, and NF-κb Transcriptional Activity: Crosstalk between the Immune and Endocrine Systems

9:00AM-11:00AM: Abstract Number: 176

SEC16A and Antigen Presentation Abnormalities in the Pathogenesis of Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 174

Transcriptional Profiling of Synovial Macrophages from RA Patients to Capture Disease Heterogeneity

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].